Conic Public Biotech Fund LP
Raised
Pre-open
Investors
—
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
AltStreet Analysis
·Generated from EDGAR primary sources
Conic Public Biotech Fund LP is a Delaware-organized pooled investment fund that filed a Form D on 2026-10-29 under the Rule 506(b) exemption. The filing is a pre-open disclosure with no first sale date, no disclosed amount sold, no investor count, and no stated minimum investment, and it does not appear to be part of a previously identified platform. Executive officers listed are Conic GP LLC (general partner), Rohan Shah, and Brennan Overhoff.
This filing sits in the private pooled-fund segment of alternative investments, using the common 506(b) exemption that permits sales to accredited investors without general solicitation. With no amount sold, investor count, or minimum investment yet disclosed, the offering appears to be newly registered and pre-fundraising, which is typical for an early-stage Form D filing in this category.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
N/A Conic GP LLC
Executive Officer · Atherton, CA
Rohan Shah
Executive Officer · Atherton, CA
Brennan Overhoff
Executive Officer · Atherton, CA
Questions About Conic Public Biotech Fund LP
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Conic Public Biotech Fund LP?
Conic Public Biotech Fund LP is an issuer that filed a Form D with the SEC on October 29, 2026. The filing claims 506(b).
Is Conic Public Biotech Fund LP legit?
AltStreet does not rate legitimacy; it reports the public record. Conic Public Biotech Fund LP filed a Form D with the SEC on October 29, 2026 claiming 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Conic Public Biotech Fund LP registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Conic Public Biotech Fund LP claimed 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Conic Public Biotech Fund LP raised?
Conic Public Biotech Fund LP reported no amount sold as of the Form D filed October 29, 2026.
Who is selling Conic Public Biotech Fund LP and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.
Where is Conic Public Biotech Fund LP located?
The issuer's address on its SEC filings is 349 Selby Lane, Atherton, CA 94027. Its phone number of record is 716.341.7916. It is organized under the laws of Delaware.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.